Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study
Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study
复制标题
DOI：
10.1111/jnc.15478
复制
发表时间：
2021-07-28
影响因子：
4.7
通讯作者：
Qiu, Wei
中科院分区：
文献类型：
--
作者：
Liu, Chunxin;Lu, Yaxin;Qiu, Wei
本文探讨了视神经脊髓炎谱系障碍(NMOSD)和多发性硬化症(MS)患者血清神经丝轻链(SNFL)和胶质纤维酸性蛋白(SGFAP)水平与临床病程和治疗的关系。采用超灵敏的单分子阵列技术检测102例NMOSD患者、98例MS患者和84例健康对照组的SNFL和sGFAP水平。值得注意的是，13名NMOSD患者和27名MS患者参加了为期1年的随访队列。将水平与临床病程、病程、扩展残疾状态量表(EDSS)评分和MRI上的病变等数据进行比较。NMOSD和MS患者的SNFL和sGFAP水平高于HCS患者(SNFL，中位数12.11，17.5pg/ml对8.88pg/ml，p<；0.05；sGFAP，中位数130.2,160.4对80.01pg/ml，p<；0.05)。MS复发期sNFL水平高于NMOSD复发期(30.02pg/ml比14.57pg/ml，p<0.05)，缓解期sGFAP水平高于NMOSD缓解期(159.8 pg/ml比124.5 pg/ml，p<0.01)。多变量分析表明，复发时较高的sGFAP/SNFL商数与NMOSD的EDSS评分相关(p<；0.05)。随访1年时，缓解期NMOSD患者SNFL和sGFAP水平均下降，而MS缓解期患者仅SNFL下降。SGFAP和SNFL是诊断和监测NMOSD和MS的潜在血液生物标志物。
We investigated the serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels in a cohort of Chinese patients with neuromyelitis optica spectrum disorders (NMOSD) and multiple sclerosis (MS) in relation to clinical disease course and treatment. sNfL and sGFAP levels were determined by ultrasensitive single molecule array (Simoa) assay in patients with NMOSD (n = 102) and MS (n = 98) and healthy controls (HCs; n = 84). Notably, 13 patients with NMOSD and 27 patients with MS were enrolled in the 1-year follow-up cohort. Levels were compared with data such as clinical course, disease duration, Expanded Disability Status Scale (EDSS) score, and lesions on MRI. Higher levels of sNfL and sGFAP were found in subjects with NMOSD and MS than in HCs (sNfL, median 12.11, 17.5 vs. 8.88 pg/ml, p < .05; sGFAP, median 130.2, 160.4 vs. 80.01 pg/ml, p < .05). Moreover, sNfL levels were higher in the relapse phase of MS than in the relapse phase of NMOSD (30.02 vs. 14.57 pg/ml, p < .05); sGFAP levels were higher in the remission phase of MS than in the remission phase of NMOSD (159.8 vs. 124.5 pg/ml, p < .01). A higher sGFAP/sNfL quotient at relapse differentiated NMOSD from MS. Multivariate analyses indicated that sGFAP levels were associated with the EDSS score in NMOSD (p < .05). At the 1-year follow-up, sNfL and sGFAP levels were both decreased in NMOSD patients in remission, while only sNfL levels were decreased in MS patients in remission. sGFAP and sNfL are potential blood biomarkers for diagnosing and monitoring NMOSD and MS.